These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 37047074)

  • 1. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond.
    Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stop codon readthrough as a treatment option for epidermolysis bullosa-Where we are and where we are going.
    Zandanell J; Wießner M; Bauer JW; Wagner RN
    Exp Dermatol; 2024 Mar; 33(3):e15042. PubMed ID: 38459626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutics based on stop codon readthrough.
    Keeling KM; Xue X; Gunn G; Bedwell DM
    Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsense suppression therapies in human genetic diseases.
    Martins-Dias P; Romão L
    Cell Mol Life Sci; 2021 May; 78(10):4677-4701. PubMed ID: 33751142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sense from nonsense: therapies for premature stop codon diseases.
    Bidou L; Allamand V; Rousset JP; Namy O
    Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
    Keeling KM; Bedwell DM
    Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allele-specific therapy: suppression of nonsense mutations by readthrough inducers].
    Floquet C; Rousset JP; Bidou L
    Med Sci (Paris); 2012 Feb; 28(2):193-9. PubMed ID: 22377308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.
    Sharma J; Du M; Wong E; Mutyam V; Li Y; Chen J; Wangen J; Thrasher K; Fu L; Peng N; Tang L; Liu K; Mathew B; Bostwick RJ; Augelli-Szafran CE; Bihler H; Liang F; Mahiou J; Saltz J; Rab A; Hong J; Sorscher EJ; Mendenhall EM; Coppola CJ; Keeling KM; Green R; Mense M; Suto MJ; Rowe SM; Bedwell DM
    Nat Commun; 2021 Jul; 12(1):4358. PubMed ID: 34272367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of small molecule eRF3 degraders on premature termination codon readthrough.
    Baradaran-Heravi A; Balgi AD; Hosseini-Farahabadi S; Choi K; Has C; Roberge M
    Nucleic Acids Res; 2021 Apr; 49(7):3692-3708. PubMed ID: 33764477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of premature termination codons as a therapeutic approach.
    Keeling KM; Wang D; Conard SE; Bedwell DM
    Crit Rev Biochem Mol Biol; 2012 Sep; 47(5):444-63. PubMed ID: 22672057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides.
    Wangen JR; Green R
    Elife; 2020 Jan; 9():. PubMed ID: 31971508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A system for coordinated analysis of translational readthrough and nonsense-mediated mRNA decay.
    Baker SL; Hogg JR
    PLoS One; 2017; 12(3):e0173980. PubMed ID: 28323884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
    Rowe SM; Clancy JP
    BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introducing sense into nonsense in treatments of human genetic diseases.
    Linde L; Kerem B
    Trends Genet; 2008 Nov; 24(11):552-63. PubMed ID: 18937996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
    Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
    Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
    RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders.
    Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH
    Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsense suppression therapies in ocular genetic diseases.
    Wang X; Gregory-Evans CY
    Cell Mol Life Sci; 2015 May; 72(10):1931-8. PubMed ID: 25651836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations.
    Lebeda D; Fierenz A; Werfel L; Rosin-Arbesfeld R; Hofhuis J; Thoms S
    J Mol Med (Berl); 2024 May; 102(5):641-653. PubMed ID: 38430393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.